The Autistic Neuron
Mark Bear, Director, Picower Institute,Picower Professor of Neuroscience; The Picower Center for Learning and Memory;
Description: This self"described "basic neuroscientist" confesses he never thought he'd give a talk on autism, but as Mark Bear recounts, decades of research in the basics are now paying off with important insights into the etiology and treatment of brain disorders, including autism.
Bear provides a primer on this developmental disorder, noting that its roots are biological, it is highly heritable, and astonishingly prevalent: one in 150 people express some of the symptoms of autism. These fall on a spectrum, from severely reduced social behavior, abnormal language, repetitive movements, seizures and mental retardation, to the milder Asperger's Syndrome, where individuals are often academically successful, but socially awkward. Particularly significant to Bear: Autism's underlying genetic changes manifest themselves in problematic communication between neurons.
To unravel autism, researchers are examining its clinical heterogeneity, "genetic risk architecture," and how it alters brain connections and function. One of the difficulties in approaching autism is that a variety of genetic mutations can result in autistic behaviors, and only a few of these mutations have been identified. Bear himself has been probing the single gene disorder, Fragile X syndrome (responsible for about 5% of the cases "of full"blown autism.") In Fragile X, the FMR1 gene is silenced, leading to a missing protein that serves as a key regulator of brain proteins involved in neuron communication. Without FMR1, "the brakes are missing," and there's excessive protein synthesis leading to altered brain function.
Bear hypothesized that it might be possible to correct Fragile X by bringing the system back in balance. He created mice models of the disease, and found that by reducing the number of neurotransmitter receptors that respond to the excessive brain proteins, he could ameliorate or correct Fragile X defects. These receptors are "druggable targets," and, says Bear, "if the treatment works in fly, fish or mouse, it better work in humans or Darwin was wrong."
Based on this work, drug companies are devising compounds to test in human clinical trials of Fragile X syndrome. In addition, Bear notes, colleagues have discovered that other mutations connected with autism also involve protein regulation problems. "This gets us excited, because it looks like a common pathway that causes synaptic dysfunction in different diseases that may ultimately manifest as autism. If that's the case, then treatment for the disorder may be efficacious in multiple disorders."
About the Speaker(s): Before his arrival at MIT, Mark Bear was on the faculty of Brown University School of Medicine for 17 years. After receiving his B.S. from Duke University, he earned his Ph.D. in neurobiology at Brown. He took postdoctoral training at the Max Planck Institute for Brain Research in Frankfurt, Germany, and from Leon Cooper at Brown. His honors include young investigator awards from the Office of Naval Research and the Society for Neuroscience. He is a member of the Dana Alliance for Brain Initiatives and the Neuroscience Research Program at the Neurosciences Institute, San Diego, California.
Host(s): School of Science, Department of Brain and Cognitive Sciences
It looks like no one has posted a comment yet. You can be the first!
More from MIT World — special events and lectures
Added over 3 years ago | 00:58:23 | 6166 views
Added over 3 years ago | 01:50:00 | 2188 views
Added over 3 years ago | 01:02:00 | 2484 views
Added over 3 years ago | 01:08:00 | 1840 views
Added over 3 years ago | 01:15:00 | 2999 views
Added over 3 years ago | 01:11:00 | 2820 views